A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Part of paid clinical trials in Avondale, Arizona.

Sponsor
MoonLake Immunotherapeutics AG
Study ID
NCT07223138
Phase
PHASE3
Status
Enrolling By Invitation

Conditions

  • Arthritis, Psoriatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sonelokimab — DRUG
    Open-label

Study Details

This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)

Key Dates

Start date
Nov 13, 2025
Status verified
Jun 2026
Primary completion
Feb 4, 2028
Completion
Feb 4, 2028

Study Design

Enrollment
1,560 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: sonelokimab dose
    All participants will receive sonelokimab subcutaneously every 4 weeks

Primary Outcome Measure

Long-term safety and tolerability of sonelokimab: [ Time Frame: 52 weeks ]

Locations (16)

FacilityCityStateZIPSite coordinators
Clinical SiteAvondaleArizona85392-
Clinical SiteMesaArizona85210-
Clinical SitePhoenixArizona85032-
Clinical SiteTucsonArizona85748-
Clinical SiteJonesboroArkansas72401-
Clinical SiteUplandCalifornia91786-
Clinical SiteAvon ParkFlorida33825-
Clinical SiteClearwaterFlorida33765-
Clinical SiteTampaFlorida33607-
Clinical SiteCharlotteNorth Carolina28262-
Clinical SiteLelandNorth Carolina28451-
Clinical SiteMiddleburg HeightsOhio44130-
Clinical SiteDuncansvillePennsylvania16635-
Clinical SiteMemphisTennessee38119-
Clinical SiteBaytownTexas77521-
Clinical SiteLubbockTexas79424-

Find similar trials in Avondale, AZ

By research site
Clinical Site· Avondale, AZClinical Site· Mesa, AZClinical Site· Phoenix, AZClinical Site· Tucson, AZClinical Site· Jonesboro, ARClinical Site· Upland, CA

Related Studies